Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Lycotec Turns Red Wine to Medicine

Published: Saturday, March 15, 2014
Last Updated: Saturday, March 15, 2014
Bookmark and Share
Unique Resveratrol formulation effective in treating the most severe complication of diabetes: foot ulcers - results of clinical trial are published.

The French Paradox is a phenomenon that people in France, who have highest consumption of red wine per person, have the lowest cardiovascular mortality rate and one of the longest in longevity in the Western world. One of the key molecules behind this is a grape flavonoid molecule trans-Resveratrol, t-RSV.

Numerous experimental laboratory studies of this molecule have generated promising results for potential applications of t-RSV from prevention and treatment of numerous diseases such as diabetes, cardiovascular pathologies and cancer, to use in anti-ageing products.

However, studies in humans have so far not provided convincing evidence of clinical benefits of t-RSV. This frustration has been attributed to the fact that when this molecule is used not as a part of red wine, but in its isolated form, it gets modified by the factors of the gastro-intestinal tract, GIT, and loses its metabolic activity.

To circumvent this problem the Cambridge based company Lycotec has developed an oral delivery technology, Lycosome™, which can protect valuable but vulnerable molecules to minimize their modification by GIT. When its inventor and the CEO of the company, Dr Ivan Petyaev, applied this technology for t-RSV, the level of its unmodified form in the blood of volunteers was increased by up to 10 fold.

Having developed this potentiated form of t-RSV, Lycotec undertook an ambitious trial to test this product in the treatment of Foot Ulcer, the most severe clinical complication of Diabetes.

This condition has no specific pharmaceutical treatment and is the leading cause of lower limb amputation in the world.

A limb is lost every 30 minutes due to a mine explosion; a limb is lost every 20 seconds due to diabetes.

Diabetes affect 28 million people in the US, 2.6 million in the UK and 280 million people worldwide. 60-70% of those with diabetes will develop peripheral neuropathy, or loss of sensation in their feet. 25% of people with diabetes develop a foot ulcer, and 1 in 5 will require an amputation because of the development of its persistent and progressing infection.

Every year there are more than 90,000 amputations in the US, and 5,000 in the UK due to diabetes. After the first amputation, 50% of people will have their other limb amputated within 2 years.

The 5 year mortality rate after the first amputation is 68% - second only to lung cancer, 86% (breast cancer 23%, prostate cancer 8%).

The first pivotal randomized, blind, placebo controlled study on 24 patients with diabetic foot ulcer was led by the principle investigator Dr Yuriy Bashmakov, and the results have now been published in the journal of Endocrinology (

The study has shown that daily administration of only 50 mg twice a day of t-RSV-Lycosome™, on top of regular care and general diabetes treatment, resulted in an almost complete closure of the ulcer by 95%. In the placebo group the reduction of the size of the ulcer was noticeable but by only 50% from the pre-treatment level. At the same time there was a significant change in the Foot Pressure Test in the t-RSV group but no change in the placebo group.

Lycotec recognizes that these results need to be confirmed and further evaluated in larger clinical trials. However, this first trial provided new hope, not only for patients with this severe diabetic complication, for which no specific pharmaceutical treatment exists, but also for people with other diseases where the rationale of the use of t-RSV has been demonstrated. Moreover, the high potency new generation of t-RSV -Lycosome™, due to its status of food supplement status can not only be used as a drug, but for prevention, health maintenance, performance boost and anti-ageing nutritional products.

Lycotec is currently looking for licensing out and partnering opportunities for t-RSV -Lycosome™ to be taken to the next development and commercialization level with Pharmaceutical, Nutrition and Cosmetic Industries.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos